Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies.
Little AJ, Vesely MD. Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies. The Yale Journal Of Biology And Medicine 2020, 93: 81-95. PMID: 32226339, PMCID: PMC7087060.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCutaneous lupus erythematosusDevelopment of CLEDisease pathogenesisAdaptive immune componentsClinical trial landscapeUnmet medical needFuture therapeutic strategiesPromising clinical trialsFuture pathogenesisLupus erythematosusSignificant morbidityAutoimmune diseasesImmune cellsClinical trialsCurrent treatmentTrial landscapeImmune componentsTherapeutic strategiesDrug AdministrationMedical needDiseasePathogenesisEnvironmental triggersTherapyType IHIF-1 regulates pathogenic cytotoxic T cells in lupus skin disease
Little A, Chen P, Vesely M, Khan R, Fiedler J, Garritano J, Islam F, McNiff J, Craft J. HIF-1 regulates pathogenic cytotoxic T cells in lupus skin disease. JCI Insight 2023, 8: e166076. PMID: 37526979, PMCID: PMC10543720, DOI: 10.1172/jci.insight.166076.Peer-Reviewed Original ResearchConceptsCutaneous lupus erythematosusLupus skin diseaseT cellsSkin diseasesCytotoxic signatureInflammatory infiltrateHIF-1Tissue damageKidney-infiltrating T cellsSkin-infiltrating T cellsAutoimmune skin diseaseHIF-1 inhibitionSkin tissue damageLupus erythematosusSystemic diseaseTissue inflammationGranzyme BMouse modelInflammatory gene programDiseaseProtein levelsInfiltratesSkin environmentGene programPresent study